Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source
Contact: Ding Ma, PhD
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Yanli Qu
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766· Phase 3· Genmab· Source
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· Phase 1/2· Huahui Health· Source
Contact: Xiyu Zhang PM
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· RemeGen Co., Ltd.· Source
Contact: Yongfeng Yang
Recruiting
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
NCT07281976· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: dongtao meng
Recruiting
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
NCT07557914· Phase 2· Haibo Shao· Source
Contact: Wenheng Zheng
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Hongxu Liu, Site 0103
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065· Phase 2· Guangzhou Lupeng Pharmaceutical Company LTD.· Source
Contact: Xiaojing Xing
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301· Phase 3· Takeda· Source
Contact: Hongxu Liu
Active, not recruiting
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
NCT07162883· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Tao Sun, Site 1014
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679· Phase 2/3· Beijing Biostar Pharmaceuticals Co., Ltd.· Source
Contact: Jingdong Zhang (principal investigator)
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· Phase 3· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Qian Dong
Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820· Phase 1/2· Akeso· Source
Contact: Wenting Li,M.D.
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Rui Ma, Site 0493
Recruiting
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
NCT06940102· Changchun GeneScience Pharmaceutical Co., Ltd.· Source
Contact: Cheng Du
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Active, not recruiting
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
NCT06702618· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005· Phase 1/2· Shenzhen Ionova Life Sciences Co., Ltd.· Source
Contact: Yu Zeng
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Tao Sun
Recruiting
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
NCT06783569· Phase 1· JiaRay Group· Source
Contact: Jingdong Zhang, MD (principal investigator)
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Yuan Liang, Site 0181
Active, not recruiting
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136· Phase 1/2· Servier Bio-Innovation LLC· Source
Recruiting
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Jingdong Zhang
Not yet recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Danbo Wang, Doctor
Active, not recruiting
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06378177· Phase 2· Lyvgen Biopharma Holdings Limited· Source
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· Phase 2/3· Hutchmed· Source
Contact: Xiangdong Hua
Recruiting
Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer
NCT06241781· Phase 2· Grit Biotechnology· Source
Contact: Chunyan Wang, PHD
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
NCT06241846· Phase 2· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Coordinator Clinical operation director
Recruiting
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
NCT06112704· Phase 2· Hansoh BioMedical R&D Company· Source
Contact: Yun Sun
Recruiting
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729· Phase 2· Hansoh BioMedical R&D Company· Source
Contact: Siwei Bao
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190· Phase 2· Hansoh BioMedical R&D Company· Source
Contact: Lingying Wu, MD
Recruiting
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: xue kong
Active, not recruiting
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
NCT06057571· Phase 2· TransThera Sciences (Nanjing), Inc.· Source
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Xiaoling Li
Not yet recruiting
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· Phase 3· Akeso· Source
Contact: Zhifang Yao, M.D.
Recruiting
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
NCT06560827· Phase 1· CARsgen Therapeutics Co., Ltd.· Source
Contact: Xiangdong Hua
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xiangdong Hua, Doctor
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Pfizer· Source
Recruiting
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05112991· Phase 2· 3D Medicines (Sichuan) Co., Ltd.· Source
Contact: Danbo Wang
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432· Phase 1/2· Betta Pharmaceuticals Co., Ltd.· Source
Contact: Wanlin Chen, Master
Enrolling by invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459· Phase 3· Chinese Academy of Medical Sciences· Source
Active, not recruiting
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Showing 50 of 55.